NCT06775379: An ongoing trial by Xenon Pharmaceuticals Inc.
This trial is ongoing. It must report results 1 year, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06775379 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 20, 2024 |
| Completion date | Aug. 31, 2026 |
| Required reporting date | Aug. 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |